

SUPPLEMENTARY MATERIAL

Bioguided Fractionation of Hypoglycaemic Component in Methanol Extract of *Vernonia amygdalina*: An *in vivo* study

Stanley I.R. Okoduwa ^{a,b*}, Ismaila A. Umar ^a, Dorcas B. James ^a, Hajiya M. Inuwa ^a, James D. Habila ^c,
Alessandro Venditti ^d

^a Department of Biochemistry, Ahmadu Bello University, Zaria, Nigeria

^b Directorate of Research and Development, Nigerian Institute of Leather and Science
Technology, Zaria, Nigeria

^c Department of Chemistry, Ahmadu Bello University, Zaria, Nigeria

^d Department of Chemistry, “Sapienza” University of Rome, Rome, Italy

*Correspondence: Email: siroplc@gmail.com

Abstract

Nine components (C1-C9) were isolated from chloroform fraction of fractionated methanol extracts of *Vernonia amygdalina* leaves (FMEVA) by column chromatography. All the components C1 to C9 were purified and screened for hypoglycaemic activities in type-2 diabetic rats. The most potent hypoglycaemic component was elucidated on the basis of extensive spectroscopic (1D-, 2D-NMR, GC-MS, FTIR) data analysis. The Component C5 was found to be the most potent hypoglycaemic in reducing blood glucose by $12.55 \pm 3.55\%$ at 4 h post-oral administration, when compared to the positive ($18.07 \pm 1.20\%$) and negative ($-1.99 \pm 0.43\%$) controls. The spectroscopic data analysis reveals that the isolated compound has a structure consistent with 11 β ,13-dihydrovernonolide. The isolated compound is part of the hypoglycaemic components present in *V. amygdalina* leaves that is responsible for the anti-diabetic activities. Further research is needed in the development of this compound or its derivatives for pharmaceutical use.

Keywords: Anti-diabetic; hyperglycaemia; hypoglycaemic; *Vernonia amygdalina*; Type-2 diabetes

CONTENTS

PAGES

Figure S1:	¹ H-NMR Spectra for Purified Component C-5 from Column Fractionated Chloroform Fraction of <i>V. amygdalina</i> Methanol Leaf Extract	3
Figure S2:	¹³ C-NMR Spectra for Purified Component C-5 from Column Fractionated Chloroform Fraction of <i>V. amygdalina</i> Methanol Leaf Extract	4
Figure S3:	DEPT-NMR Spectra for Purified Component C5 from Column Fractionated Chloroform Fraction of <i>Vernonia amygdalina</i> Methanol Leaf Extract	5
Figure S4:	Carbons numbering and chemical structure of 11 β ,13-dihydroveranolide.	6
Figure S5:	Selected HMBC correlations for 11 β ,13-dihydroveranolide.	7
Figure S6:	Observed fragmentation pathway for 11 β ,13-dihydroveranolide.	8
Figure S7:	FTIR Spectra for Purified Component C-5 from Column Fractionated Chloroform Fraction of <i>V. amygdalina</i> Methanol Leaf Extract.	9
Table S1:	Change (%) in Fasting Blood Glucose in Type-2 Diabetic Rats after Treatment with Purified Components from Column Fractionated Chloroform Fraction of <i>V. amygdalina</i> Methanol Leaf Extract	10
Table S2:	Decrease (%) in Fasting Blood Glucose in Type-2 Diabetic Rats after Treatment with Different Doses of Purified Component C5 from Column Fractionated Chloroform Fraction of <i>V. amygdalina</i> Methanol Leaf Extract	11
Table S3:	¹³ C- NMR data for Purified Component C5 from <i>V. amygdalina</i> Methanol Leaf Extract	12
Table S4:	Functional Groups Identified Using FTIR Spectra Analysis for Purified Component C-5 from Column Fractionated Chloroform Fraction of <i>V. amygdalina</i> Methanol Leaf Extract. Wavenumbers (cm ⁻¹)	13
References		14

Figures




Figure S1: ¹H-NMR Spectra for Purified Component C-5 from Column Fractionated Chloroform Fraction of *V. amygdalina* Methanol Leaf Extract




Figure S2: ^{13}C -NMR Spectra for Purified Component C-5 from Column Fractionated Chloroform Fraction of *V. amygdalina* Methanol Leaf Extract




Figure S3: DEPT-NMR Spectra for Purified Component C5 from Column Fractionated Chloroform Fraction of *Vernonia amygdalina* Methanol Leaf Extract




Figure S4: Carbons numbering and chemical structure of 11 β ,13-dihydroveranolide.




Figure S5: Selected HMBC correlations for 11 β ,13-dihydroveranolide.




Figure S6: Observed fragmentation pathway for 11 β ,13-dihydroveranolide.




Figure S7: FTIR Spectra for Purified Component C-5 from Column Fractionated Chloroform Fraction of *V. amygdalina* Methanol Leaf Extract.

Tables

Table S1: Change (%) in Fasting Blood Glucose in Type-2 Diabetic Rats After Treatment with Purified Components from Column Fractionated Chloroform Fraction of *V. amygdalina* Methanol Leaf Extract (10 mg/kg bw)

VACF purified components	0.5 h	1 h	2 h	3 h	4 h
C1	0.07±0.42 ^{cd}	0.84±0.48 ^a	1.30±0.37 ^a	2.10±0.64 ^a	3.75±1.13 ^{ab}
C2	0.59±0.23 ^{ab}	2.40±1.97 ^a	6.79±1.72 ^{bcd}	8.96±1.96 ^{cd}	9.50±1.75 ^{cd}
C3	0.22±0.27 ^{bcd}	2.20±1.78 ^a	3.77±0.86 ^{ab}	6.15±3.48 ^{bc}	5.79±3.42 ^{abc}
C4	0.91±0.15 ^a	1.50±0.12 ^a	2.42±0.38 ^a	4.63±0.87 ^{ab}	4.74±0.58 ^{ab}
C5	0.20±0.21 ^{de}	5.76±3.10 ^b	8.63±2.67 ^{cd}	11.52±2.98 ^d	12.55±3.55 ^d
C6	0.17±0.21 ^{bcd}	0.55±0.17 ^a	1.87±2.01 ^a	2.94±1.71 ^{ab}	3.10±2.55 ^{ab}
C7	1.79 ± 0.25 ^f	5.41±2.79 ^b	6.24±3.95 ^{bc}	6.77±3.94 ^{bc}	6.96±4.41 ^{bc}
C8	0.49±0.30 ^e	1.42±0.28 ^a	2.62±1.04 ^a	3.40±1.21 ^{ab}	3.58±1.68 ^{ab}
C9	0.32±0.18 ^{bc}	1.32±0.55 ^a	2.48±0.74 ^a	3.09±0.41 ^{ab}	3.33±0.64 ^{ab}
DC	0.31±0.10 ^{bc}	1.00±0.70 ^a	1.15±0.73 ^a	1.90±0.25 ^a	2.11±0.35 ^a
PC	3.09±0.32 ^g	7.41±1.04 ^b	9.50±0.08 ^d	17.48±0.92 ^e	17.80±0.96 ^e

Data are presented as mean ± SD of 3 animals per group. Values with different superscript down the column indicate significant difference ($p < 0.05$). VACF: Chloroform fraction of *V. amygdalina* methanol Leaf extract; PC: Positive control; DC: Diabetic control; C1, C2, ... and C9: Purified components from column fractionated VACF.

Table S2: Decrease (%) in Fasting Blood Glucose in Type-2 Diabetic Rats after Treatment with Different Doses of Purified Component C5 from Column Fractionated Chloroform Fraction of *V. amygdalina* Methanol Leaf Extract

Group	0.5 h	1 h	2 h	3 h	4 h
G₅	0.51 ± 0.21 ^a	1.06 ± 1.21 ^a	2.35 ± 1.29 ^a	3.96 ± 0.24 ^b	4.10 ± 1.57 ^b
G₁₀	0.70 ± 0.27 ^{a,b}	4.92 ± 2.23 ^b	7.84 ± 1.58 ^b	10.55 ± 1.19 ^c	11.97 ± 1.64 ^c
G₂₀	1.23 ± 0.24 ^b	5.32 ± 2.27 ^b	9.38 ± 1.60 ^{b,c}	13.41 ± 2.75 ^d	13.62 ± 1.44 ^c
DC	0.28 ± 0.23 ^a	0.84 ± 0.29 ^a	1.02 ± 0.13 ^a	1.27 ± 0.16 ^a	1.98 ± 0.12 ^a
PC	2.81 ± 0.82 ^c	6.72 ± 2.53 ^b	10.40 ± 1.20 ^c	15.21 ± 2.48 ^d	18.33 ± 1.53 ^d

Data are presented as mean ± SD of 5 animals per group. Values with different superscript down the column indicate significant difference ($p < 0.05$). PC: Positive control; DC: Diabetic control; G₅, G₁₀, ... and G₂₀ are diabetic rat groups treated with three different doses (5, 10 and 20 mg/kg b.w.) respectively of Purified Components C5 from Chloroform fraction of *V. amygdalina* methanol Leaf extract.

Table S3: ^{13}C - NMR data for Purified Component C5 from *V. amygdalina* Methanol Leaf Extract

Position	*	Experimental Data		
	^{13}C -NMR, 125 MHz, δ	^{13}C -NMR, HSQC, 100 MHz, δ	DEPT	HMBC
1	66.32	66.32	CH	
2	22.74	22.70	CH ₂	
3	33.56	33.56	CH ₂	
4	142.85	142.94	C	
5	129.23	129.25	CH	C15
6	77.31	78.51	CH	C4, C8, C11
7	57.11	57.06	CH	
8	71.50	71.50	CH	C16
9	40.79	40.78	CH ₂	C14
10	58.89	59.02	C	
11	39.93	40.78	CH	C12
12	177.54	177.87	C	
13	16.72	16.75	CH ₃	C7, C11, C12
14	99.47	99.39	CH	
15	64.30	64.29	CH ₂	C3, C4, C5,C14
16	167.96	167.93	C	
17	135.62	135.63	C	
18	18.28	18.39	CH ₃	C16, C17, C19,
19	127.44	127.58	CH ₂	C16, C17, C18,

*Rabe *et al*, 2002

Table S4: Functional Groups Identified Using FTIR Spectra Analysis for Purified Component C-5 from Column Fractionated Chloroform Fraction of *V. amygdalina* Methanol Leaf Extract. Wavenumbers (cm^{-1})

	Absorbance	Absorption Ranges	Functional Group
1	3354.60	3100-3500	O-H
2	2926.00	2500-3300	C-H
3	1777.90	1670-1820	C=O
4	1707.10	1700-1725	C=O
5	1446.2	1440-1480	=C=H ₂
6	969.1	960-990	=C=H ₂
7	808.8	790-840	-C=CH-

Functional Group region: 4000 cm^{-1} - 1400 cm^{-1} ; Finger print region: 1400 cm^{-1} - 400 cm^{-1}

References

Rabe, T., Mullholland, D., Van-Staden, J., 2002. Isolation and identification of antibacterial compounds from *Vernonia colorata* leaves. *Journal of Ethnopharmacology*, 80(1): 91-94.